- Home
- PASG vs NRSN Comparison
PASG vs NRSN Comparison
Compare PASG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | NRSN |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | Israel |
| Employees | 27 | 15 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 28.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PASG | NRSN |
|---|---|---|
| Price | $7.83 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $23.50 | $8.50 |
| AVG Volume (30 Days) | 30.3K | ★ 120.7K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.68 |
| 52 Week High | $20.00 | $2.60 |
Technical Indicators
Market Signals| Indicator | PASG | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 38.95 |
| Support Level | $6.71 | $0.68 |
| Resistance Level | $7.72 | $1.30 |
| Average True Range (ATR) | 0.77 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 16.73 | 13.76 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.